Avecho Biotechnology Ltd has released a press release.
Positive results from AVEs topical CBD pain study
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- Dosing begins in topical CBD pain study
- Appendix 4E and Annual Report 31 December 2021
- AVE license agreement for US recreational cannabis market
- December 2021 Quarterly Activities Report & Appendix 4C
- Application for quotation of securities - AVE
Later from Avecho Biotechnology
- March 2022 Quarterly Activities Report & Appendix 4C
- Suspension from Official Quotation - AVEO
- Update on Listed Options and Federal Court Application
- Security Class Reinstatement to Quotation- AVEO
- June 2022 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology